Opicapone Improved Parkinson’s Disease-related Sleep Disturbances: Findings from the OASIS Study (P11-5.020)
To evaluate the potential benefits of the COMT inhibitor opicapone (OPC) on sleep, when added to existing levodopa in Parkinson’s disease (PD) patients with end-of-dose motor fluctuations and associated sleep disturbances.
Authors
- Helena C. Brigas (ORCID: https://orcid.org/0000-0002-4176-6649)
- Miguel Gago (ORCID: https://orcid.org/0000-0003-0894-6207)
- Joana Almeida
- Joaquim Ferreira
- Raquel Costa (ORCID: https://orcid.org/0000-0001-7602-7945)
- José‐Francisco Rocha (ORCID: https://orcid.org/0000-0003-2611-4850)
- Joerg Holenz
- Miguel Fonseca
- Ghazal Banisadr
Institutions
- University of Lisbon (PT)
- Amneal (India) (IN)
- Hospital da Senhora da Oliveira Guimarães (PT)
- University of Minho (PT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210482
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00